letetresgene autoleucel
Cell therapyexperimental
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
5
Phase 3
0
Phase 4
0
Earliest trial started Dec 31, 2018 (NCT03709706)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Cancer/testis antigen 1Immunity, passive
Cancer/testis antigen 1 immunity, passive
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4650238 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05993299 | Phase 2 | Dec 31, 2019 | GlaxoSmithKline |
| NCT06703346 | Phase 2 | Dec 31, 2019 | Adaptimmune |
| NCT03967223 | Phase 2 | Sep 30, 2019 | GlaxoSmithKline |
| NCT03697824 | Phase 2 | Feb 25, 2019 | GlaxoSmithKline, Merck |
| NCT03709706 | Phase 2 | Dec 31, 2018 | GlaxoSmithKline, Merck |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 4 | 4 | 1 | 2018 |
| Merck | For profit | 2 | 0 | 1 | 2018 |
| Adaptimmune | For profit | 1 | 1 | 1 | 2019 |
3 organizations
Page 1 / 1